PR Newswire
LAS VEGAS, March 17, 2026
The growth of the epidermolysis bullosa market is expected to be mainly driven by increasing prevalence, patient awareness, label expansion of approved therapies, high cost of therapies, and robust clinical pipeline, including D-Fi/FCX-007 (Castle Creek Biosciences), EBESANAR (RHEACELL and AOP Health), Redasemtide (SHIONOGI/StemRIM), KB803 (Krystal Biotech), AGLE-102 (Aegle Therapeutics), AC-203 (TWi Biotechnology), and others in the coming years.
LAS VEGAS, March 17, 2026 /PRNewswire/ — Recently published Epidermolysis Bullosa Market Insights report includes a comprehensive understanding of current treatment practices, epidermolysis bullosa emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Epidermolysis Bullosa Market Summary
- The total epidermolysis bullosa treatment market size is expected to grow positively by 2034 in the leading markets.
- The United States accounted for the largest epidermolysis bullosa treatment market size in 2024, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- The total prevalent population of epidermolysis bullosa in the 7MM comprised ~47,000 cases in 2024.
- Leading epidermolysis bullosa companies, such as Castle Creek Biosciences, RHEACELL, AOP Health, SHIONOGI, StemRIM, Krystal Biotech, Aegle Therapeutics, TWi Biotechnology, and others, are developing new epidermolysis bullosa treatment drugs that can be available in the epidermolysis bullosa market in the coming years.
- The promising epidermolysis bullosa therapies in clinical trials include D-Fi/FCX-007, EBESANAR, Redasemtide, KB803, AGLE-102, AC-203, and others.
Discover what is the projected size of the epidermolysis bullosa market by 2036 @ https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market
Key Factors Driving the Growth of the Epidermolysis Bullosa Market
- Rising Epidermolysis Bullosa Prevalence: The total prevalent population of epidermolysis bullosa in the 7MM comprised ~47,000 cases in 2024. These cases are projected to increase for the study period of 2020-2034.
- Impact of Allele Frequency Estimation on Rare Disease Detection: Estimating the frequency of genetic alleles could improve the detection of underdiagnosed rare genetic diseases in general and, more specifically, RDEB. This enhancement in diagnosis could lead to better estimates of the incidence and prevalence of patients who might benefit from treatment.
- Approval of Gene Therapy VYJUVEK: Gene therapies for epidermolysis bullosa are becoming a reality with the approval of VYJUVEK, the first FDA-approved topical gene therapy.
- Launch of Epidermolysis Bullosa Drugs: The dynamics of the epidermolysis bullosa market are expected to change in the coming years, owing to the launch of emerging therapies such as D-Fi/FCX-007 (Castle Creek Biosciences), EBESANAR (RHEACELL and AOP Health), Redasemtide (SHIONOGI/StemRIM), KB803 (Krystal Biotech), AGLE-102 (Aegle Therapeutics), AC-203 (TWi Biotechnology), and others.
Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight, said that stem cell-based therapies are becoming increasingly important, especially for previously incurable diseases. Due to the special immunomodulatory and anti-inflammatory properties, ABCB5+ mesenchymal stromal cells (ABCB5+ MSCs) represent a new, promising therapeutic approach for various chronic inflammatory diseases, including epidermolysis bullosa.
Epidermolysis Bullosa Market Analysis
- Current therapeutic options for epidermolysis bullosa remain limited, with most available interventions aimed at supportive care.
- Management typically centers on wound care, alleviating pain and itching, preventing and treating infections, ensuring adequate nutrition, and addressing related complications.
- At present, four treatments have received regulatory approval for epidermolysis bullosa, the most recent being ZEVASKYN, authorized in April 2025.
- VYJUVEK was approved by the FDA in May 2023 for patients aged six months and older with dystrophic epidermolysis bullosa (DEB). FILSUVEZ secured approval in the European Union in June 2022 and later received FDA approval in December 2023, becoming the first therapy approved in the U.S. for wounds associated with both junctional epidermolysis bullosa (JEB) and DEB.
- Earlier, in December 2018, Japan issued the world’s first approval for a cell-based therapy for epidermolysis bullosa when Japan Tissue Engineering, a Fujifilm subsidiary, was authorized to produce and market the autologous cultured epidermis product JACE.
- Globally, numerous companies continue to advance innovative therapeutic approaches for epidermolysis bullosa, with notable progress achieved in recent years.
- Leading developers include Castle Creek Biosciences (Dabocemagene autoficel), RHEACELL and AOP Health (EBESANAR), SHIONOGI/StemRIM (Redasemtide), Krystal Biotech (KB803), Aegle Therapeutics (AGLE-102), TWi Biotechnology (AC-203), and others.
Epidermolysis Bullosa Competitive Landscape
Some of the epidermolysis bullosa drugs under development include D-Fi/FCX-007 (Castle Creek Biosciences), EBESANAR (RHEACELL and AOP Health), Redasemtide (SHIONOGI/StemRIM), KB803 (Krystal Biotech), AGLE-102 (Aegle Therapeutics), AC-203 (TWi Biotechnology), and others.
Castle Creek Biosciences’ D-Fi, also referred to as FCX-007 (dabocemagene autoficel), is an autologous gene-therapy candidate being developed for the treatment of DEB. It is made from a patient’s own dermal fibroblasts, which are genetically engineered using a self-inactivating lentiviral vector carrying the COL7A1 gene, enabling the cells to produce type VII collagen. The therapy is delivered through intradermal injections into the superficial papillary dermis of chronic wounds, where the introduced COL7 protein can help form anchoring fibrils in the skin. The FDA has granted D-Fi Orphan Drug Designation for both DEB and RDEB, as well as RPDD, Fast Track, and RMAT designations specifically for RDEB.
RHEACELL and AOP Health’s EBESANAR is a systemic treatment intended for individuals with RDEB and JEB. It is administered every two months via intravenous infusion and aims to improve skin lesions, lower overall disease burden, and prevent ongoing tissue damage. A Phase III clinical trial is currently underway in the United States and Europe, with top-line data expected in late 2025 and a European marketing authorization submission planned for Q1 2026.
SHIONOGI/StemRIM’s Redasemtide is a regenerative therapy in development that promotes tissue repair without relying on living cells. It has received Orphan Drug Designation for DEB from the MHLW.
TWi Biotechnology’s AC-203 is a proprietary topical version of AC-201, which inhibits caspase-1 activity and reduces production of the cytokine IL-1β by blocking NLRP3 inflammasome activation. Suppression of this pathway and subsequent IL-1β release is effective across several conditions, including arthritis, gout, and diabetes mellitus. The oral form of AC-201 has been approved for treating chronic rheumatic diseases in France and later in various European and Middle Eastern countries, including Spain and Italy, since the mid-1990s.
The anticipated launch of these emerging therapies are poised to transform the epidermolysis bullosa market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the epidermolysis bullosa market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about which new EB therapies have been approved recently @ Epidermolysis Bullosa Drugs
Recent Developments in the Epidermolysis Bullosa Market
- In September 2025, Krystal Biotech announced that the FDA had approved an update to the labeling for beremagenegeperpavec-svdt (B-VEC/YJUVEK).
- In August 2025, BioMendics initiated the TAMES-02 clinical trial, a multicenter, randomized, double-blind, placebo-controlled study designed to assess the safety and effectiveness of TolaSure, a first-in-class topical treatment for individuals with generalized intermediate to severe Epidermolysis Bullosa Simplex.
- In July 2025, StemRIM announced that patient enrollment for the additional Phase II clinical trial on Redasemtide, which was previously out-licensed to Shionogi for DEB, has been completed.
- In May 2025, RHEACELL announced that it had entered into an exclusive partnership agreement with the AOP Health Group, which will commercialize RHEACELL’s two stem cell products, EBESANAR and AMESANAR, in Europe, Turkey, Israel, and the MENA region (Middle East and Northern Africa).
- In February 2025, Castle Creek Biosciences secured USD 75 million in financing to support a Phase III trial testing its gene therapy to promote wound healing in people with DEB. The royalty financing agreement for Castle Creek’s treatment, D-Fi, was led by Ligand Pharmaceuticals, making a USD 50 million investment.
What is Epidermolysis Bullosa?
Epidermolysis bullosa is a rare group of genetic disorders that makes the skin extremely fragile and prone to blistering from even minor friction or injury. Because the proteins that normally anchor the layers of skin together are missing or not working properly, the skin can split and form painful blisters with everyday activities like walking, holding objects, or rubbing clothing. Epidermolysis bullosa can range from mild forms that mainly affect the hands and feet to severe forms involving widespread blistering, internal complications, and significant medical needs. While there is currently no cure, supportive care, wound management, and emerging therapies aim to improve comfort and quality of life for those living with the condition.
Epidermolysis Bullosa Epidemiology Segmentation
The epidermolysis bullosa epidemiology section provides insights into the historical and current epidermolysis bullosa patient pool and forecasted trends for the leading markets. Across the 7MM (excluding the US), recessive DEB (RDEB) was more common than dominant DEB (DDEB).
The epidermolysis bullosa treatment market report proffers epidemiological analysis for the study period 2020-2034 in the leading markets, segmented into:
- Total Prevalent Cases of Epidermolysis Bullosa
- Diagnosed Prevalent Cases of Epidermolysis Bullosa
- Type-specific Cases of Epidermolysis Bullosa
- Gender-specific Cases of Epidermolysis Bullosa
- Age-specific Cases of Epidermolysis Bullosa
Epidermolysis Bullosa Market Report Metrics
Details
Study Period
2020-2034
Coverage 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Epidermolysis Bullosa Epidemiology Segmentation Total Prevalent Cases of Epidermolysis Bullosa, Diagnosed Prevalent Cases of Epidermolysis Bullosa, Type-
specific Cases of Epidermolysis Bullosa, Gender-specific Cases of Epidermolysis Bullosa, and Age-
specific Cases of Epidermolysis Bullosa
Key Epidermolysis Bullosa Companies Castle Creek Biosciences, RHEACELL, AOP Health, SHIONOGI, StemRIM, Krystal Biotech, Aegle Therapeutics,
TWi Biotechnology, Chiesi, Japan Tissue Engineering, Abeona Therapeutics, and others
Key Epidermolysis Bullosa Therapies D-Fi/FCX-007, EBESANAR, Redasemtide, KB803, AGLE-102, AC-203, VYJUVEK, FILSUVEZ, JACE, ZEVASKYN, and
others
Scope of the
Epidermolysis Bullosa
Market Report
- Therapeutic Assessment: Epidermolysis Bullosa current marketed and emerging therapies
- Epidermolysis Bullosa Market Dynamics: Key Market Forecast Assumptions of Emerging Epidermolysis Bullosa Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Epidermolysis Bullosa Market Access and Reimbursement
Download the report to understand which companies are driving growth in the epidermolysis bullosa market @ Epidermolysis Bullosa Market Analysis
Table of Contents
1
Epidermolysis Bullosa Market Key Insights
2
Epidermolysis Bullosa Market Report Introduction
3
Executive Summary of Epidermolysis Bullosa
4
Key Events
5
Epidemiology and Market Forecast Methodology
6 Epidermolysis Bullosa Market Overview at a Glance
6.1 Market Share (%) Distribution by Therapies in 2024
6.2 Market Share (%) Distribution by Therapies in 2034
7 Epidermolysis Bullosa: Disease Background and Overview
7.1
Introduction
7.2
Causes of Epidermolysis Bullosa
7.3
Signs and Symptoms of Epidermolysis Bullosa
7.4
Pathogenesis of Epidermolysis Bullosa
7.5 Pathophysiology of Itch in Epidermolysis Bullosa Skin
7.6
Classification of Epidermolysis Bullosa
7.7
Genetic Bases of Epidermolysis Bullosa
7.8
Diagnosis of Epidermolysis Bullosa
8 Treatment and Management of Epidermolysis Bullosa
9
Guidelines
10
Epidemiology and Patient Population of 7MM
10.1
Key Findings
10.2
Assumption and Rationale
10.3 Total Prevalent Cases of Epidermolysis Bullosa in the 7MM
10.4 Diagnosed Prevalent Cases of Epidermolysis Bullosa in the
7MM
10.5
The United States
10.5.1 Total Prevalent Cases of Epidermolysis Bullosa in the
United States
10.5.2 Diagnosed Prevalent Cases of Epidermolysis Bullosa in the
United States
10.5.3 Type-specific Cases of Epidermolysis Bullosa in the United
States
10.5.4 Gender-specific Cases of Epidermolysis Bullosa in the
United States
10.5.5 Age-specific Cases of Epidermolysis Bullosa in the United
States
10.6
EU4 and the UK
10.7
Japan
11
Epidermolysis Bullosa Patient Journey
12
Marketed Epidermolysis Bullosa Drugs
12.1
Key Competitors
12.2
VYJUVEK (beremagene geperpavec): Krystal Biotech
12.2.1
Product Description
12.2.2
Regulatory Milestones
12.2.3
Other Developmental Activities
12.2.4
Clinical Developmental Activities
12.2.4.1
Clinical Trial Information
12.2.5
Safety and Efficacy
12.2.6
Analyst Views
12.3
FILSUVEZ (oleogel-S10): Chiesi
12.4 JACE (human epidermal cell sheet): Japan Tissue Engineering
12.5
ZEVASKYN: Abeona Therapeutics
13
Emerging Epidermolysis Bullosa Drugs
13.1
Key Competitors
13.2 D-Fi (dabocemagene autoficel): Castle Creek Biosciences
13.2.1
Product Description
13.2.2
Other Developmental Activities
13.2.3
Clinical Developmental Activities
13.2.3.1
Clinical Trial Information
13.2.4
Safety and Efficacy
13.2.5
Analyst Views
13.3
Redasemtide: Shionogi
13.4
KB803: Krystal Biotech
13.5
EBESANAR: RHEACELL and AOP Health
13.6
AGLE-102: Aegle Therapeutics
14
Epidermolysis Bullosa Market: 7MM Analysis
14.1
Key Findings
14.2
Epidermolysis Bullosa Market Outlook
14.3
Key Market Forecast Assumptions
14.4
Conjoint Analysis
14.5 Total Market Size of Epidermolysis Bullosa in the 7MM
14.6
United States Epidermolysis Bullosa Market Size
14.6.1 Total Market Size of Epidermolysis Bullosa in the United
States
14.6.2 Market Size of Epidermolysis Bullosa by Therapies in the
United States
14.7
EU4 and the UK Epidermolysis Bullosa Market Size
14.8
Japan Epidermolysis Bullosa Market Size
15
Epidermolysis Bullosa Market Unmet Needs
16
Epidermolysis Bullosa Market SWOT Analysis
17
KOL Views on Epidermolysis Bullosa
18 Epidermolysis Bullosa Market Access and Reimbursement
18.1
United States
18.2
EU4 and the UK
18.3
Japan
18.4 Epidermolysis Bullosa Market Access and Reimbursement
19
Bibliography
20
Epidermolysis Bullosa Market Report Methodology
Related Reports
Epidermolysis Bullosa Clinical Trial Analysis
Epidermolysis Bullosa Pipeline Insight
–
2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key epidermolysis bullosa companies, including Abeona Therapeutics, InMed Pharmaceuticals, BioMendics, RHEACELL, Castle Creek Biosciences, BPGbio, Eloxx Pharmaceuticals, Phoenicis Therapeutics, Aegle Therapeutics, Amryt Pharma, among others.
Dystrophic Epidermolysis Bullosa
Market
Dystrophic Epidermolysis Bullosa
Market Insights, Epidemiology, and Market Forecast
–
2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DEB companies including Castle Creek Biosciences, Amryth Pharma, Krystal Biotech, Abeona Therapeutics, BridgeBio, Phoenix Tissue Repair, and others.
Atopic Dermatitis Market
Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key atopic dermatitis companies including Kyowa Kirin, Amgen, Sanofi, UNION Therapeutics, Biosion, LEO Pharma, Connect Biopharma, Nektar Therapeutics, Apogee Therapeutics, Roche, Genentech, Eli Lilly and Company, Almirall, Organon, Torii Pharmaceutical, Chugai Pharmaceutical, Galderma, Maruho, AbbVie, Pfizer, Regeneron Pharmaceuticals, Incyte, Japan Tobacco, Otsuka Pharmaceutical, Medimetriks Pharmaceuticals, Acrotech Biopharma, and others.
Moderate to Severe Atopic Dermatitis Market
Moderate to Severe Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key moderate to severe atopic dermatitis companies, including Jiangsu Vcare Pharmaceutical Technology Co., LTD, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., Nektar Therapeutics, E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Corvus Pharmaceuticals, Inc., UCB Biopharma SRL, Tavotek Biotherapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd, SCM Lifescience Co., LTD., Sanofi, Amgen, Qurient Co., Ltd., Sun Pharmaceutical Industries Limited, Pfizer, UNION therapeutics, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact UsShruti Thakur [email protected] +14699457679www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/epidermolysis-bullosa-market-set-for-significant-upswing-during-the-forecast-period-20252034-amid-rising-therapeutic-advancements–delveinsight-302715539.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…